Abstract: Objective To observe the effect and adverse reactions of anlotinib combined with anti-PD-1 antibody in treatment of advanced hepatocellular carcinoma. Methods Clinical data about 13 patients with advanced hepatocellular carcinoma treated with anlotinib combined with anti-PD-1 antibody from January to August in 2019 in our department were selected,and the curative effect and adverse reactions were observed.The follow-up lasted to September 27th,2019. Results The main adverse reactions of anlotinib combined with anti-PD-1 antibody in the treatment of advanced hepatocellular carcinoma were hand-foot syndrome,skin reaction and hypertension.No grade 3-4 adverse reactions occurred.In the 13 cases,3 cases achieved partial remission,and 6 cases achieved stable disease.The objective effective rate was 23.1%,and the disease control rate was 69.2%. Conclusion Anlotinib combined with anti-PD-1 antibody (AK105) shows good curative effect in the treatment of advanced hepatocellular carcinoma with controllable adverse reactions.